Positive news continues to roll out for COVID-19 vaccine development and distribution efforts, with Sanofi and GSK announcing the success of their vaccine candidate against the Omicron variant.

Outcomes from Stage 2 of the Phase III study of VAT08 including over 13,000 adult participants confirmed the vaccine’s action, demonstrating a 64.7% efficacy versus symptomatic COVID-19 and 72% efficacy versus Omicron-linked symptomatic cases. Results from the Stage 1 group showcased similar results.

In both stages, VAT08 had a favorable tolerability and safety profile. Given the positive results, Sanofi said it would begin discussions with regulatory authorities with the goal of making the product available before the year ends.

Read more here